Patents by Inventor Jeannine Alexander

Jeannine Alexander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Continuous adherent melanocyte cell line
    Patent number: 6541250
    Abstract: The present invention comprises a novel immortal non-adherent human melanocyte cell line, designated WC-1 14.07. This cell line is stable and MHC class I negative. This continuous melanocyte cell line can be used as a source of melanin and hgp100. The Class I MHC-negative nature of this cell line allows it to be used as a target for transfection with MHC class I genes, providing a novel source of hgp100 in a pre-determined MHC context. The cell line can thus be used in a variety of ways, directly or indirectly, in the development and manufacture of vaccines for melanoma.
    Type: Grant
    Filed: April 18, 2001
    Date of Patent: April 1, 2003
    Assignee: Aventis Pasteur Limited
    Inventors: Jeannine Alexander, William I. Cox
  • Continuous adherent melanocyte cell line
    Publication number: 20020006662
    Abstract: The present invention comprises a novel immortal non-adherent human melanocyte cell line, designated WC-1 14.07. This cell line is stable and MHC class I negative. This continuous melanocyte cell line can be used as a source of melanin and hgp100. The Class I MHC-negative nature of this cell line allows it to be used as a target for transfection with MHC class I genes, providing a novel source of hgp100 in a pre-determined MHC context. The cell line can thus be used in a variety of ways, directly or indirectly, in the development and manufacture of vaccines for melanoma.
    Type: Application
    Filed: April 18, 2001
    Publication date: January 17, 2002
    Inventors: Jeannine Alexander, William I. Cox
  • Formyl methionyl peptide vaccine adjuvant
    Patent number: 6017537
    Abstract: The present invention relates to immunological adjuvants comprised of the N-formyl methionyl peptide fMLP. FMLP, when used as an adjuvant in accordance with the present invention, provides for an immune response to suboptimal doses of recombinant antigens.
    Type: Grant
    Filed: December 18, 1998
    Date of Patent: January 25, 2000
    Assignee: Connaught Laboratories, Inc.
    Inventors: Jeannine Alexander, William I. Cox